344 related articles for article (PubMed ID: 33986726)
1. Recent Understanding and Future Directions of Recurrent Corticotroph Tumors.
Hinojosa-Amaya JM; Lam-Chung CE; Cuevas-Ramos D
Front Endocrinol (Lausanne); 2021; 12():657382. PubMed ID: 33986726
[TBL] [Abstract][Full Text] [Related]
2. Cyclin E-Mediated Human Proopiomelanocortin Regulation as a Therapeutic Target for Cushing Disease.
Liu NA; Araki T; Cuevas-Ramos D; Hong J; Ben-Shlomo A; Tone Y; Tone M; Melmed S
J Clin Endocrinol Metab; 2015 Jul; 100(7):2557-64. PubMed ID: 25942479
[TBL] [Abstract][Full Text] [Related]
3. Relevance of mutations in protein deubiquitinases genes and
Pękul M; Szczepaniak M; Kober P; Rusetska N; Mossakowska BJ; Baluszek S; Kowalik A; Maksymowicz M; Zieliński G; Kunicki J; Witek P; Bujko M
Front Endocrinol (Lausanne); 2024; 15():1302667. PubMed ID: 38487343
[TBL] [Abstract][Full Text] [Related]
4. The expression of glucocorticoid and mineralocorticoid receptors in pituitary tumors causing Cushing's disease and silent corticotroph tumors.
Kober P; Rusetska N; Mossakowska BJ; Maksymowicz M; Pękul M; Zieliński G; Styk A; Kunicki J; Działach Ł; Witek P; Bujko M
Front Endocrinol (Lausanne); 2023; 14():1124646. PubMed ID: 37065760
[TBL] [Abstract][Full Text] [Related]
5. Why don't corticotroph tumors always produce Cushing's disease?
García-Martínez A; Cano DA; Flores-Martínez A; Gil J; Puig-Domingo M; Webb SM; Soto-Moreno A; Picó A
Eur J Endocrinol; 2019 Sep; 181(3):351-361. PubMed ID: 31319379
[TBL] [Abstract][Full Text] [Related]
6. Lapatinib decreases the ACTH production and proliferation of corticotroph tumor cells.
Asari Y; Kageyama K; Sugiyama A; Kogawa H; Niioka K; Daimon M
Endocr J; 2019 Jun; 66(6):515-522. PubMed ID: 30880293
[TBL] [Abstract][Full Text] [Related]
7. Targeting Corticotroph HDAC and PI3-Kinase in Cushing Disease.
Zhang D; Damoiseaux R; Babayan L; Rivera-Meza EK; Yang Y; Bergsneider M; Wang MB; Yong WH; Kelly K; Heaney AP
J Clin Endocrinol Metab; 2021 Jan; 106(1):e232-e246. PubMed ID: 33000123
[TBL] [Abstract][Full Text] [Related]
8. Aggressive Cushing's Disease: Molecular Pathology and Its Therapeutic Approach.
Yamamoto M; Nakao T; Ogawa W; Fukuoka H
Front Endocrinol (Lausanne); 2021; 12():650791. PubMed ID: 34220707
[TBL] [Abstract][Full Text] [Related]
9. Targeting zebrafish and murine pituitary corticotroph tumors with a cyclin-dependent kinase (CDK) inhibitor.
Liu NA; Jiang H; Ben-Shlomo A; Wawrowsky K; Fan XM; Lin S; Melmed S
Proc Natl Acad Sci U S A; 2011 May; 108(20):8414-9. PubMed ID: 21536883
[TBL] [Abstract][Full Text] [Related]
10. Ubiquitin-specific protease 8 inhibitor suppresses adrenocorticotropic hormone production and corticotroph tumor cell proliferation.
Kageyama K; Asari Y; Sugimoto Y; Niioka K; Daimon M
Endocr J; 2020 Feb; 67(2):177-184. PubMed ID: 31666445
[TBL] [Abstract][Full Text] [Related]
11. Metformin suppresses growth and adrenocorticotrophic hormone secretion in mouse pituitary corticotroph tumor AtT20 cells.
Jin K; Ruan L; Pu J; Zhong A; Wang F; Tan S; Huang H; Mu J; Yang G
Mol Cell Endocrinol; 2018 Dec; 478():53-61. PubMed ID: 30025915
[TBL] [Abstract][Full Text] [Related]
12. EGFR as a therapeutic target for human, canine, and mouse ACTH-secreting pituitary adenomas.
Fukuoka H; Cooper O; Ben-Shlomo A; Mamelak A; Ren SG; Bruyette D; Melmed S
J Clin Invest; 2011 Dec; 121(12):4712-21. PubMed ID: 22105169
[TBL] [Abstract][Full Text] [Related]
13. Crooke's Changes In Cushing's Syndrome Depends on Degree of Hypercortisolism and Individual Susceptibility.
Oldfield EH; Vance ML; Louis RG; Pledger CL; Jane JA; Lopes MB
J Clin Endocrinol Metab; 2015 Aug; 100(8):3165-71. PubMed ID: 26147609
[TBL] [Abstract][Full Text] [Related]
14. Cold inducible RNA binding protein upregulation in pituitary corticotroph adenoma induces corticotroph cell proliferation via Erk signaling pathway.
Jian F; Chen Y; Ning G; Fu W; Tang H; Chen X; Zhao Y; Zheng L; Pan S; Wang W; Bian L; Sun Q
Oncotarget; 2016 Feb; 7(8):9175-87. PubMed ID: 26824322
[TBL] [Abstract][Full Text] [Related]
15. Targeting the ERK pathway for the treatment of Cushing's disease.
Zhang D; Bergsneider M; Wang MB; Heaney AP
Oncotarget; 2016 Oct; 7(43):69149-69158. PubMed ID: 27708250
[TBL] [Abstract][Full Text] [Related]
16. The Mechanisms Underlying Autonomous Adrenocorticotropic Hormone Secretion in Cushing's Disease.
Fukuoka H; Shichi H; Yamamoto M; Takahashi Y
Int J Mol Sci; 2020 Nov; 21(23):. PubMed ID: 33266265
[TBL] [Abstract][Full Text] [Related]
17. Aberrant Nuclear Translocation of E2F1 and Its Association in Cushing's Disease.
Araki T; Wang J; Lawrence R; Kawakami Y
Endocrinology; 2022 Aug; 163(8):. PubMed ID: 35678423
[TBL] [Abstract][Full Text] [Related]
18. EGFR Induces E2F1-Mediated Corticotroph Tumorigenesis.
Araki T; Liu X; Kameda H; Tone Y; Fukuoka H; Tone M; Melmed S
J Endocr Soc; 2017 Feb; 1(2):127-143. PubMed ID: 29264472
[TBL] [Abstract][Full Text] [Related]
19. Impact of USP8 Gene Mutations on Protein Deregulation in Cushing Disease.
Weigand I; Knobloch L; Flitsch J; Saeger W; Monoranu CM; Höfner K; Herterich S; Rotermund R; Ronchi CL; Buchfelder M; Glatzel M; Hagel C; Fassnacht M; Deutschbein T; Sbiera S
J Clin Endocrinol Metab; 2019 Jul; 104(7):2535-2546. PubMed ID: 30844069
[TBL] [Abstract][Full Text] [Related]
20. [The ectopic ACTH syndrome].
Penezić Z; Savić S; Vujović S; Tatić S; Ercegovac M; Drezgićc M
Srp Arh Celok Lek; 2004; 132(1-2):28-32. PubMed ID: 15227962
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
